AccuStem Sciences

Executive Summary

AccuStem Sciences is a clinical-stage diagnostics company headquartered in London, UK, dedicated to developing and commercializing novel genomic tests for cancer. Founded in 2015, the company aims to provide integrated solutions that support decision-making across the entire oncology care continuum, from early detection to treatment planning and monitoring. AccuStem leverages cutting-edge genomic technologies to build a suite of diagnostics that empower physicians and patients with actionable insights, ultimately improving cancer management and outcomes. As a private entity currently in Phase 1 development, the company is focused on validating its core test platforms and establishing clinical utility. With a clear vision and a targeted approach to addressing unmet needs in oncology, AccuStem Sciences is positioned to contribute to the evolving landscape of precision medicine. Its strategic focus on the UK and broader European markets, combined with a commitment to innovation, underscores its potential for growth and impact in the diagnostics sector.

Upcoming Catalysts (preview)

• Q1 2027Completion of Phase 1/2 Clinical Study for Lead Genomic Test40% success
• Q4 2026Strategic Partnership with a Major Diagnostic or Pharma Company35% success
• Q2 2026Publication of Key Validation Data in Peer-Reviewed Journal50% success